genomic editing News
-
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11TH Annual Global Healthcare Conference on Thursday, February 17TH, at 2:20 pm ET. A live webcast of the discussion will be ...
-
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40TH Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. A live webcast of the presentation will be accessible ...
-
Caribou Biosciences to Participate in Citi’s 16th Annual BioPharma Virtual Conference
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a panel discussion entitled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy” on Thursday, September 9, ...
-
New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing
For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target editing efficiency. Thermo Fisher Scientific introduced the new protein to complement its growing portfolio of CRISPR genome ...
-
Feldan congratulates scge program for nature article
Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. Feldan is honoured to be part of this initiative alongside its long-standing collaborator, Dr. Paul McCray of the University of Iowa. https://www.nature.com/articles/s41586-021-03191-1 About the collaboration between Dr. McCray and Feldan ...
-
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell therapy product candidate -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading ...
-
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some ...
-
Mammoth Biosciences Named to Fierce Medtech’s “Fierce 15” Companies of 2020 for Advancing Next Generation CRISPR Products in Diagnostics and Therapeutics
Mammoth Biosciences today announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry. This designation comes after a year of immense momentum at the company as it leverages its innovative CRISPR platform in the fight against the COVID-19 pandemic and beyond. As a leader in the development of ...
-
Agilent Technologies Introduces Tools for Next-Generation Genome Engineering
Agilent Technologies Inc. (NYSE: A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology. The complete SureGuide workflow includes a SureGuide Cas9 Nuclease Kit, SureGuide gRNA Synthesis Kit and SureGuide gRNA Control Kit, all designed to work together for any lab interested in quickly enabling next-generation genome engineering. The ...
-
Editas Medicine Announces Pricing Of Offering Of Common Stock
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds from the offering are expected to be approximately $125 million. Editas ...
-
Mammoth Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Mammoth’s co-founder and CEO, Trevor Martin, will present a corporate overview virtually on January 11, 2022 at 1:30 p.m. PT (4:30 p.m. ET). About Mammoth Biosciences Mammoth ...
-
A breakthrough in biopharmaceutical protein production; LenioBio announces a new proprietary cell line devoid of plant glycans.
Dusseldorf, May 16, 2022 – the German life science biotech firm, LenioBio GmbH, today announced the generation of a novel plant glycan knockout cell line that will increase the versatility and flexibility of the company’s cell-free protein synthesis (CFPS) system, ALiCE®. LenioBio’s proprietary ALiCE® platform is derived from a tobacco BY-2 plant cell lysate. ...
-
Agilent Technologies Presents 2015 Early Career Professor Award to Dr. Mitchell Guttman of Caltech
Agilent Technologies Inc. (NYSE: A) today named Dr. Mitchell Guttman the winner of its 2015 Early Career Professor Award. The award, now in its seventh year, recognizes one early career professor for his or her exceptional, original research contributions and outstanding potential for future research. Dr. Guttman was selected from a global pool of professors contributing to the understanding and ...
-
Editas Medicine Announces Positive Initial EDIT-301 Safety And Efficacy Data From The First Four Patients Treated In The RUBY Trial And The First Patient Treated In The EdiTHAL Trial
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial. The RUBY trial data will be presented in an oral presentation at ...
-
Optimal Peptides of BOC Sciences Arouse Heated Discussions at TIDES USA 2022
BOC Sciences successfully participated in TIDES USA 2022 from May 9th to 12th, at Hynes Convention Center, Boston. During the four-day exhibition, experts from BOC Sciences and global visitors are engaged in heated discussions concerning novel advances in peptide and amino acid synthesis, discovery, design, and engineering. BOC Sciences has been preparing for the world's largest gathering of ...
By BOC Sciences
-
CRISPR Off-Target Analysis Now Available with CD Genomics’ Bioinformatics-Analysis Platform
The Bioinformatics-Analysis is a subdivision of CD Genomics, providing reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction services, and other related data analysis services. The company is pleased to announce the launch of the CRISPR off-target analysis service to help researchers optimize the CRISPR ...
By CD Genomics
-
Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics
Enables expansion of novel CRISPR platform, including proprietary ultra-small Cas14 and Cas? CRISPR systems for in vivo gene-editing therapeutics Makes key appointment of biotech veteran Gary Loeb as general counsel Mammoth Biosciences, the biotech company leveraging the diversity of life to build the next generation of CRISPR products to cure and detect disease, today announced it has ...
-
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems. “We believe our novel ultra-small CRISPR systems have the potential ...
-
Mammoth Biosciences Named as an “Endpoints 11” Most Promising Startup of 2022
Mammoth Biosciences, a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11 annual special report. Comprising a team of scientist-founders, experienced biopharma veterans, and talented researchers, Mammoth is developing a ...
-
Mammoth Biosciences Receives FDA Emergency Use Authorization for First CRISPR-based High-Throughput COVID-19 Test
Mammoth Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing. The DETECTR BOOST platform is a turnkey, CRISPR-based molecular diagnostic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you